Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1609671 | 0.98 | KMT2A (0.32) | KMT2AADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL12473823 | 0.85 | KMT2A (0.32) | KMT2AADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL12713879 | 0.70 | SMN1; SMN2 (0.42) | KMT2A | |
| SCHEMBL539004 | 0.69 | KMT2A (0.54) | KMT2AADORA2AADORA2BALDH1A1 | |
| SCHEMBL1008469 | 0.65 | ADORA2A (0.31) | ADORA2A | |
| SCHEMBL15214970 | 0.64 | KMT2A (0.31) | KMT2AADORA2A | |
| SCHEMBL21891274 | 0.63 | ADORA2A (0.35) | KMT2AADORA2AADORA2BKDM4EALDH1A1 | |
| SCHEMBL21891275 | 0.63 | ALDH1A1 (0.33) | KMT2AADORA2AADORA2BALDH1A1 | |
| SCHEMBL3192497 | 0.63 | KDM4E (0.30) | KMT2AKDM4E | |
| SCHEMBL141994 | 0.59 | GSK3A (0.44) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850279-B | Theophylline derived spontaneous combustion ionic salt and preparation method thereof | 哈尔滨工业大学（深圳） | 2024-11-15 | — | — | CN | disclosed |
| WO-2020070672-A1 | HYDRIDE DONORS AS AN ADDITIVE FOR REDUCING LOW SPEED PRE-IGNITION EVENTS | CHEVRON ORONITE COMPANY LLC (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2016184312-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | 南京明德新药研发股份有限公司 | 2016-11-24 | — | — | WO | disclosed |
| EP-1660444-B1 | METAL COMPLEXES OF N-HETEROCYCLIC CARBENES AS RADIOPHARMACEUTICALS AND ANTIBIOTICS | UNIV AKRON (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8648064-B2 | Metal complexes of N-heterocyclic carbenes | THE UNIVERSITY OF AKRON (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648064-B2 | Metal complexes of N-heterocyclic carbenes | THE UNIVERSITY OF AKRON (US) | 2014-02-11 | — | — | US | disclosed |
| CN-103327816-A | Metal complexes of N-heterocyclic carbenes | UNIV AKRON | 2013-09-25 | — | — | CN | disclosed |
| US-8519146-B2 | Purine or imidazole and silver complexes; therapeutic, antimicrobial, and antifungal compounds; urinary tract infections | THE UNIVERSITY OF AKRON (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519146-B2 | Purine or imidazole and silver complexes; therapeutic, antimicrobial, and antifungal compounds; urinary tract infections | THE UNIVERSITY OF AKRON (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2268652-B1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011046942-A1 | METAL COMPLEXES OF N-HETEROCYCLIC CARBENES | THE UNIVERSITY OF AKRON (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086830-A1 | METAL COMPLEXES OF N-HETEROCYCLIC CARBENES | THE UNIVERSITY OF AKRON (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086830-A1 | METAL COMPLEXES OF N-HETEROCYCLIC CARBENES | THE UNIVERSITY OF AKRON (US) | 2011-04-14 | — | — | US | disclosed |
| CN-101955494-A | Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics | UNIV AKRON | 2011-01-26 | — | — | CN | disclosed |
| WO-2009118475-A2 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | disclosed |
| US-20080267867-A1 | Metal Complexes of N-Heterocyclic Carbenes as Radiopharmaceuticals and Antibiotics | UNIVERSITY OF AKRON | 2008-10-30 | — | — | US | disclosed |
| US-20080267867-A1 | Metal Complexes of N-Heterocyclic Carbenes as Radiopharmaceuticals and Antibiotics | UNIVERSITY OF AKRON | 2008-10-30 | — | — | US | disclosed |
| CN-1926141-A | Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics | UNIV AKRON (US) | 2007-03-07 | — | — | CN | disclosed |
| US-20070021401-A1 | Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics | UNIVERSITY OF AKRON | 2007-01-25 | — | — | US | disclosed |
| US-20070021401-A1 | Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics | UNIVERSITY OF AKRON | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267867-A1 | Metal Complexes of N-Heterocyclic Carbenes as Radiopharmaceuticals and Antibiotics | MKI67, C1S, CYC1 | KMT2A 3072/4885ADORA2A 2258/4885ADORA2B 1986/4885 |
| US-20070021401-A1 | Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics | MKI67, AHR, ARNT | KMT2A 2553/4885ADORA2A 2245/4885ADORA2B 1920/4885 |
| US-20110086830-A1 | METAL COMPLEXES OF N-HETEROCYCLIC CARBENES | NOD2, ARNT, FPR1 | KMT2A 2765/4885ADORA2A 993/4885ADORA2B 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.